GI 201
Alternative Names: GI-201Latest Information Update: 28 Apr 2024
At a glance
- Originator GI Innovation
- Class Anti-inflammatories; Antidementias; Hepatoprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases; Short bowel syndrome
- Discontinued Alzheimer's disease; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in South Korea
- 28 Apr 2024 No recent reports of development identified for preclinical development in Short-bowel-syndrome in South Korea
- 16 Mar 2020 Discontinued - Preclinical for Alzheimer's disease in South Korea (GI Innovation pipeline, March 2020)